Misplaced Pages

Revision as of 14:31, 2 July 2018

Hidradenitis suppurativa
Other names	Acne inversa, acne conglobata, apocrine acne, Velpeau’s disease
Hidradenitis suppurativa (stage II) in the left armpit
Specialty	Dermatology
Symptoms	Multiple inflamed and swollen skin lesions
Usual onset	Young adulthood
Duration	Long-term
Types	Stage I, II, III
Causes	Unknown
Diagnostic method	Based on symptoms
Differential diagnosis	Acne, acne conglobata, pilonidal cysts
Treatment	Warm baths, laser therapy, surgery
Medication	Antibiotics, immunosuppressive medication
Frequency	1-4% of people
Deaths	Rare

Hidradenitis suppurativa (HS), also known as acne inversa, is a long term skin disease characterized by the occurrence of inflamed and swollen lumps. These are typically painful and break open releasing fluid or pus. The areas most commonly affected are the underarms, under the breasts, and groin. Scar tissue remains after healing. Self-consciousness or depression may result.

The exact cause is usually unclear but believed to involve a combination of genetic and environmental factors. About a third of people with the disease have an affected family member. Other risk factors include obesity and smoking. The condition is not infectious, related to hygiene, or to the use of deodorant. The underlying mechanism is believed to involve either a dysfunction of apocrine sweat glands or hair follicles. Diagnosis is based on the symptoms.

There is no known cure. Warm baths may be tried in those with mild disease. Cutting open the lesions to allow them to drain does not result in significant benefit. While antibiotics are commonly used, evidence for their use is poor. Immunosuppressive medication may also be tried. In those with more severe disease laser therapy or surgery to remove the affected skin may be carried out. Rarely a skin lesion may develop into skin cancer.

It is estimated to affect between 1% and 4% of people. Females have the condition about three times more often than males. Onset is typically in young adulthood and may become less common after 50 years old. It was first described some time between 1833 and 1839 by Alfred Velpeau.

Causes

The cause of HS remains unknown and experts disagree over proposed causes. The condition probably results from a combination of genetic and environmental factors.

Lesions occur in any body areas with hair follicles, although areas such as the axilla, groin, and perianal region are more commonly involved. This theory includes most of the following potential indicators:

• Postpubescent individuals are more likely to exhibit HS.
• Plugged apocrine (sweat) gland or hair follicle
• Excessive sweating
• Androgen dysfunction
• Genetic disorders that alter cell structure
• Patients with more advanced cases may find exercise intolerably painful, which may increase the rate of obesity among sufferers.

The historical understanding of the disease suggests dysfunctional apocrine glands or dysfunctional hair follicles, possibly triggered by a blocked gland, create inflammation, pain, and a swollen lesion.

Triggering factors

Several triggering factors should be taken into consideration:

• Obesity is an exacerbating rather than a triggering factor, through mechanical irritation, occlusion, and maceration.
• Tight clothing, and clothing made of heavy, non-breathable materials.
• Deodorants, depilation products, shaving of the affected area – their association with hidradenitis suppurativa is still an ongoing debate amongst researchers.
• Drugs, in particular oral contraceptives (i.e., oral hormonal birth control; "the pill") and lithium.
• Hot and especially humid climates (dry/arid climates often cause remission).

Predisposing factors

• Genetic factors: an autosomal dominant inheritance pattern has been proposed.
• Endocrine factors: sex hormones, especially an excess of androgens, are thought to be involved, although the apocrine glands are not sensitive to these hormones. Women often have outbreaks before their menstrual period and after pregnancy; HS severity usually decreases during pregnancy and after menopause.

Some cases have been found to result from mutations in the NCSTN, PSEN1, or PSENEN gene. The genes produce proteins that are all components of a complex called gamma- (γ-) secretase. This complex cuts apart (cleaves) many different proteins, which is an important step in several chemical signaling pathways. One of these pathways, known as Notch signaling, is essential for the normal maturation and division of hair follicle cells and other types of skin cells. Notch signaling is also involved in normal immune system function. Studies suggest that mutations in the NCSTN, PSEN1, or PSENEN gene impair Notch signaling in hair follicles. Although little is known about the mechanism, abnormal Notch signaling appears to promote the development of nodules and lead to inflammation in the skin.

Diagnosis

Stages

HS presents itself in three stages. Due to the large spectrum of clinical severity and the severe impact on quality of life, a reliable method for evaluating HS severity is needed.

Hurley's staging system

This is historically the first classification system proposed, and is still in use for the classification of patients with skin/dermatologic diseases (i.e., psoriasis, HS, acne). Hurley separated patients into three groups based largely on the presence and extent of cicatrization and sinuses. It has been used as a basis for clinical trials in the past and is a useful basis to approach therapy for patients. These three stages are based on Hurley's staging system, which is simple and relies on the subjective extent of the diseased tissue the patient has. Hurley's three stages of hidradenitis suppurativa are:

Sartorius staging system

The Sartorius staging system is more sophisticated than Hurley's. Sartorius et al. suggested that the Hurley system is not sophisticated enough to assess treatment effects in clinical trials during research. This classification allows for better dynamic monitoring of the disease severity in individual patients. The elements of this staging system are:

• Anatomic regions involved (axilla, groin gluteal, or other region or inframammary region left or right)
• Number and types of lesions involved (abscesses, nodules, fistulas , scars, points for lesions of all regions involved)
• The distance between lesions, in particular the longest distance between two relevant lesions (i.e., nodules and fistulas in each region or size if only one lesion present)
• The presence of normal skin in between lesions (i.e., are all lesions clearly separated by normal skin?)

Points are accumulated in each of the above categories, and added to give both a regional and total score. In addition, the authors recommend adding a visual analog scale for pain or using the dermatology life quality index (DLQI, or the Skindex) when assessing HS.

Treatments

Treatment depends upon presentation and severity of the disease. Due to the poorly studied nature of the disease, the effectiveness of the drugs and therapies listed below is unclear. Possible treatments include the following:

Lifestyle

Warm baths may be tried in those with mild disease. Weight loss and stopping smoking is also recommended.

Medication

• Antibiotics: taken by mouth, these are used for their anti-inflammatory properties rather than to treat infection. Most effective is a combination of rifampicin and clindamycin given concurrently for 2–3 months. A few popular antibiotics include tetracycline, minocycline, and clindamycin. Topical clindamycin has been shown to have an effect in double-blind placebo controlled studies.
• Corticosteroid injections. Also known as intralesional steroids: can be particularly useful for localized disease, if the drug can be prevented from escaping via the sinuses.
• Antiandrogen therapy: hormonal therapy with cyproterone acetate and ethinylestradiol proved effective in randomized, controlled trials. Dosages reported have been very high.
• Intravenous or subcutaneous infusion of anti-inflammatory (anti-TNF-alpha) drugs such as infliximab, and etanercept. This use of these drugs is not currently Food and Drug Administration approved and is somewhat controversial, so may not be covered by insurance.
• TNF inhibitor: Studies have supported that various TNF inhibitors have a positive effect on hidradenitis suppurativa lesions. Specifically adalimumab at weekly intervals is useful.
• Topical isotretinoin is usually ineffective in people with HS and is more commonly known as a medication for the treatment of acne vulgaris. Individuals affected by HS who responded to isotretinoin treatment tended to have milder cases of the condition.

Surgery

When the process becomes chronic, wide surgical excision is the procedure of choice. Wounds in the affected area do not heal by secondary intention, and immediate or delayed application of a split-thickness skin graft is an option. Another option is covering the defect with a so-called perforator flap. With this technique the (mostly totally excised) defect is covered with living tissue 'stolen' from the area nearby. For example, the axilla with a fully excised defect of 15 x 7 cm can be covered with a so-called TAP flap (thoracodorsal artery perforator flap)

Laser hair removal

The 1064 nanometer wavelength laser for hair removal may aid in the treatment of HS. A randomized control study has shown improvement in HS lesions with the use of an Nd:YAG laser.

Prognosis

In stage III disease, fistulae left undiscovered, undiagnosed, or untreated, can lead to the development of squamous cell carcinoma, a rare cancer, in the anus or other affected areas. Other stage III chronic sequelae may also include anemia, multilocalized infections, amyloidosis, and arthropathy. Stage III complications have been known to lead to sepsis, but clinical data is still uncertain.

Potential complications

• Contractures and reduced mobility of the lower limbs and axillae due to fibrosis and scarring occur. Severe lymphedema may develop in the lower limbs.
• Local and systemic infections (meningitis, bronchitis, pneumonia, etc.), are seen, which may even progress to sepsis.
• Interstitial keratitis
• Anal, rectal, or urethral fistulae
• Normochromic or hypochromic anemia
• Squamous cell carcinoma: this has been found on rare occasions in chronic hidradenitis suppurativa of the anogenital region. The mean time to the onset of this type of lesion is 10 years or more and the tumors are usually highly aggressive.
• Tumors of the lung and oral cavity, probably related to the high level of smoking among these patients, and liver cancer.
• Hypoproteinemia and amyloidosis, which can lead to renal failure and death
• Seronegative and usually asymmetric arthropathy: pauciarticular arthritis, polyarthritis/polyarthralgia syndrome

History

• From 1833 to 1839 in a series of three publications, Velpeau identified and described a disease we now know as hidradenitis suppurativa.
• In 1854, Verneuil described hidradenitis suppurativa as hidrosadénite Phlegmoneuse. This is how HS obtained its alternate name "Verneuil's disease".
• In 1922, Schiefferdecker hypothesized a pathogenic link between "acne inversa" and human sweat glands.
• In 1956, Pillsbury et al coined the term follicular occlusion triad for the common association of hidradenitis suppurativa, acne conglobata and dissecting cellulitis of the scalp. Modern clinical research still employs Pillsbury's terminology for these conditions' descriptions.
• In 1975, Plewig and Kligman, following Pillsbury's research path, modified the "acne triad", replacing it with the "acne tetrad: acne triad, plus pilonidal sinus". Plewig and Kligman's research follows in Pillsbury's footsteps, offering explanations of the symptoms associated with hidradenitis suppurativa.
• In 1989, Plewig and Steger's research led them to rename hidradenitis suppurativa, calling it "acne inversa" – which is not still used today in medical terminology, although some individuals still use this outdated term.

A surgeon from Paris, Velpeau described an unusual inflammatory process with formation of superficial axillary, submammary, and perianal abscesses, in a series of three publications from 1833 to 1839. One of his colleagues also located in Paris, named Verneuil, coined the term hidrosadénite phlegmoneuse about 15 years later. This name for the disease reflects the former pathogenetic model of acne inversa, which is considered inflammation of sweat glands as the primary cause of hidradenitis suppurativa. In 1922, Schiefferdecker suspected a pathogenic association between acne inversa and apocrine sweat glands. In 1956 Pillsbury postulated follicular occlusion as the cause of acne inversa, which they grouped together with acne conglobata and perifolliculitis capitis abscendens et suffodiens (dissecting cellulitis of the scalp) as the "acne triad". Plewig and Kligman added another element to their acne triad, pilonidal sinus. Plewig et al. noted that this new "acne tetrad" includes all the elements found in the original "acne triad", in addition to a fourth element, pilonidal sinus. In 1989, Plewig and Steger introduced the term "acne inversa", indicating a follicular source of the disease and replacing older terms such as "Verneuil disease".

Other names

Hidradenitis suppurativa has been referred to by multiple names in the literature, as well as in various cultures. Some of these are also used to describe different diseases, or specific instances of this disease.

• Acne conglobata – not really a synonym – this is a similar process but in classic acne areas of chest and back
• Acne inversa – a proposed new term which has not gained widespread favor.
• Apocrine acne – an outdated term based on the disproven concept that apocrine glands are primarily involved, though many do suffer with apocrine gland infection
• Apocrinitis – another outdate term based on the same thesis
• Fox-den disease – a term not used in medical literature, based on the deep fox den–like sinuses
• Hidradenitis supportiva – a misspelling
• Pyodermia fistulans significa – now considered archaic
• Verneuil's disease – recognizing the surgeon whose name is most often associated with the disorder as a result of his 1854–1865 studies

Histology

Terminology

Although hidradenitis suppurativa is often referred to as acne inversa, it is not a form of acne and lacks the core defining features of acne such as the presence of closed comedones and increased sebum production.

References

1. ^ "Hidradenitis Suppurativa". NORD (National Organization for Rare Disorders). 2012. Archived from the original on 19 February 2017. Retrieved 26 October 2017. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
2. ^ Gregor B.E. Jemec (12 January 2012). "Clinical Practice: Hidradenitis Suppurativa". N Engl J Med. 366 (2): 158–164. doi:10.1056/NEJMcp1014163.
3. ^ "Hidradenitis suppurativa". Genetics Home Reference. December 2013. Archived from the original on 5 September 2017. Retrieved 27 October 2017. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
4. ^ "Hidradenitis suppurativa". rarediseases.info.nih.gov. 2017. Archived from the original on 28 July 2017. Retrieved 27 October 2017. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
5. Jemec, Gregor; Revuz, Jean; Leyden, James J. (2006). Hidradenitis Suppurativa. Springer Science & Business Media. p. 5. ISBN 9783540331018. Archived from the original on 28 October 2017. {{cite book}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
6. Medline Plus (2012). "Hidradenitis suppurativa". U.S. National Library of Medicine. Archived from the original on 16 September 2012. Retrieved 19 September 2012. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
7. ^ Schawartz's principles of surgery, 8th edition, self assessment an board review, chapter 15, the skin and subcutaneous tissue, question 16
8. Mayo Clinic Staff (2012). "Definition". Mayo Clinic. Archived from the original on 10 September 2012. Retrieved 19 September 2012. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
9. ^ DermNet acne/hidradenitis-suppurativa
10. "HSF – What is Hidradenitis Suppurativa? What is HS?". Archived from the original on 6 July 2007. Retrieved 8 July 2007. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
11. ^ Slade DE, Powell BW, Mortimer PS (2003). "Hidradenitis suppurativa: pathogenesis and management". Br J Plast Surg. 56 (5): 451–61. doi:10.1016/S0007-1226(03)00177-2. PMID 12890458.
12. ^ Jemec GBE. Body weight in hidradenitis suppurativa. In: Marks R, Plewig G, editors. Acne and Related disorders. London: Martin Dunitz; 1989. pp. 375–6.
13. Koning A, Lehmann C, Rompel R, Happle R (1999). "of Hidradenitis suppurativa". Dermatology. 198 (3): 261–4. doi:10.1159/000018126. PMID 10393449.
14. Morgan WP, Leicester G (1979). "The role of depilation and deodorants in hidradenitis suppurativa". Br J Surg. 66 (12): 853–6. doi:10.1002/bjs.1800661206. PMID 509057.
15. Stellon AJ, Wakeling M (1989). "Hidradenitis suppurativa associated with use of oral contraceptives". Br Med J. 298 (6665): 28–9. doi:10.1136/bmj.298.6665.28.
16. Gupta AK, Knowles SR, Gupta MA, Jaunkalns R, Shear NH (1995). "Lithium therapy associated with hidradenitis suppurativa: case report and a review of the dermatologic side effects of lithium". J Am Acad Dermatol. 32 (2 Pt 2): 382–6. doi:10.1016/0190-9622(95)90410-7. PMID 7829746.
17. Hidradenitis Suppurativa at eMedicine
18. Der Werth JM, Williams HC, Raeburn JA (2000). "The clinical genetics of hidradenitis suppurativa revisited". Br J Dermatol. 142 (5): 947–53. doi:10.1046/j.1365-2133.2000.03476.x. PMID 10809853.
19. Barth JH, Kealey T (1991). "Androgen metabolism by isolated human axillary apocrine glands in hidradenitis suppurativa". Br J Dermatol. 125 (4): 304–8. doi:10.1111/j.1365-2133.1991.tb14162.x. PMID 1954117.
20. Reference, Genetics Home. "hidradenitis suppurativa". Genetics Home Reference. Archived from the original on 5 September 2017. Retrieved 5 September 2017. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
21. ^ "HS-USA :: What is Hidradenitis Suppurativa?". Archived from the original on 17 June 2013. Retrieved 20 July 2013. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
22. Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Roenigk RK, Roenigk HH, editors. Dermatologic surgery. Marcel Dekker, New York, 1989, pp. 729–739.
23. Sartorius K, Lapins J, Emtestam L, Jemec GB (2003). "Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa". Br J Dermatol. 149 (1): 211–213. doi:10.1046/j.1365-2133.2003.05390.x. PMID 12890229.
24. Wolkenstein, P; Loundou, A; Barrau, K; Auquier, P; Revuz, J; Quality of Life Group of the French Society of Dermatology (2007). "Quality of life impairment in hidradenitis suppurativa: a study of 61 cases". Journal of the American Academy of Dermatology. 56 (4): 621–3. doi:10.1016/j.jaad.2006.08.061. PMID 17097366.
25. Ingram, JR; Woo, PN; Chua, SL; Ormerod, AD; Desai, N; Kai, AC; Hood, K; Burton, T; Kerdel, F; Garner, SE; Piguet, V (May 2016). "Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality". The British Journal of Dermatology. 174 (5): 970–8. doi:10.1111/bjd.14418. PMC 5021164. PMID 26801356.
26. Scheinfeld N (2013). "Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients". Dermatology Online Journal. 19 (4): 1. PMID 24021361.
27. Clemmenson OJ (1983). "Topical treatment of hidradenitis suppurativa with clindamycin". Int J Dermatol. 22 (5): 325–8. doi:10.1111/j.1365-4362.1983.tb02150.x. PMID 6347922.
28. Mortimer PS, Dawber RP, Gales MA, Moore RA (1986). "A double blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa". Br J Dermatol. 115 (3): 263–8. doi:10.1111/j.1365-2133.1986.tb05740.x. PMID 2944534.
29. Cusack C, Buckley C (2006). "Etanercept: effective in the management of hidradenitis suppurativa". Br. J. Dermatol. 154 (4): 726–9. doi:10.1111/j.1365-2133.2005.07067.x. PMID 16536817.
30. Haslund P, Lee RA, Jemec GB (November 2009). "Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors". Acta Derm. Venereol. 89 (6): 595–600. doi:10.2340/00015555-0747. PMID 19997689.
31. Ingram, JR (1 May 2017). "Interventions for Hidradenitis Suppurativa: Updated Summary of an Original Cochrane Review". JAMA Dermatology. 153 (5): 458–459. doi:10.1001/jamadermatol.2017.0432. PMID 28355440.
32. Nickle SB, Peterson N, Peterson M (April 2014). "Updated Physician's Guide to the Off-label Uses of Oral Isotretinoin". J Clin Aesthet Dermatol. 7 (4): 22–34. PMC 3990537. PMID 24765227.
33. "Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients". escholarship.org. Archived from the original on 6 March 2014. Retrieved 4 March 2014. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
34. Xu LY, Wright DR, Mahmoud BH, Ozog DM, Mehregan DA, Hamzavi IH (January 2011). "Histopathologic study of hidradenitis suppurativa following long-pulsed 1064-nm Nd:YAG laser treatment". Arch Dermatol. 147 (1): 21–8. doi:10.1001/archdermatol.2010.245. PMID 20855672.
35. Talmant JC, Bruant-Rodier C, Nunziata AC, Rodier JF, Wilk A (2006). "". Ann Chir Plast Esthet (in French). 51 (1): 82–6. doi:10.1016/j.anplas.2005.11.002. PMID 16488526.
36. Short KA, Kalu G, Mortimer PS, Higgins EM (2005). "Vulval squamous cell carcinoma arising in chronic hidradenitis suppurativa". Clin. Exp. Dermatol. 30 (5): 481–3. doi:10.1111/j.1365-2230.2005.01875.x. PMID 16045671.
37. Hurley HJJ. Apocrine glands. New York: McGraw Hill; 1979.
38. Tennant F Jr; Bergeron JR; Stone OJ; Mullins JF (1968). "Anemia associated with hidradenitis suppurativa". Arch Dermatol. 98 (2): 138–40. doi:10.1001/archderm.98.2.138. PMID 5667225.
39. Williams ST, Busby RC, DeMuth RJ, Nelson H (1991). "Perineal hidradenitis suppurativa: presentation of two unusual complications and a review". Ann Plast Surg. 26 (5): 456–62. doi:10.1097/00000637-199105000-00008. PMID 1952719.
40. Lapins J, Ye W, Nyren O, Emtestam L (2001). "Incidence of cancer among patients with hidradenitis suppurativa". Arch Dermatol. 137 (6): 730–4. PMID 11405761.
41. Moschella SL (1966). "Hidradenitis suppurativa. Complications resulting in death". JAMA. 198 (1): 201–3. doi:10.1001/jama.198.1.201. PMID 5953172.
42. Vasey FB, Fenske NA, Clement GB, Bridgeford PH, Germain BF, Espinoza LR (1984). "Immunological studies of the arthritis of acne conglobata and hidradenitis suppurativa". Clin Exp Rheumatol. 2 (4): 309–11. PMID 6241861.
43. Velpeau A. Aissele. In: Bechet Jeune Z: Dictionnaire de médecine, on Repertoire Générale des Sciences Medicals sous le Rapport Theorique et Pratique. 1839.
44. Verneuil AS (1854). "Etudes sur les tumeurs de la peau et quelques maladies de glandes sudoripares" [Studies on skin tumors; some diseases of the sweat glands]. Archives of General Medicine (in French). 94: 693–705.
45. Schiefferdecker B (1922). Die Hautdrüsen der Menschen und der Säugetiere, ihre histologische und rassenanatomische Bedeutung sowie die muscularis sexualis [The skin glands of humans and mammals, their histological and anatomical racial meaning and muscularis sexualis]. Stuttgart: Schweizerbart E.
46. Pillsbury DM, Shelley WB, Kligmann AM (1956). "Bacterial infections of the skin". In Pillsbury DM (ed.). Dermatoloy (1st ed.). Philadelphia. pp. 482–9.{{cite book}}: CS1 maint: location missing publisher (link)
47. Triads in Dermatology; Prachi G Agrawal, Uday S Khopkar, , and Sunil N Mishra; ; J Dermatol. 2013 Sep-Oct; 58(5): 346–351
48. Plewig, Gerd; Kligman, Albert M. (1975). "Acne Conglobata". In Plewig, Gerd; Kligman, Albert M. (eds.). Acne: Morphogenesis and Treatment. pp. 168–203. doi:10.1007/978-3-642-96246-2_11. ISBN 978-3-642-96246-2.
49. ^ Plewig G, Steger M (1989). "Acne inversa (alias acne triad, acne tetrad or hidradenitis suppurativa)". In Marks R, Plewig G (eds.). Acne and Related Disorders. London: Martin Dunitz. pp. 345–57.
50. Sellheyer K, Krahl D (2005). ""Hidradenitis suppurativa" is acne inversa! An appeal to (finally) abandon a misnomer". International Journal of Dermatology. 44 (7): 535–40. doi:10.1111/j.1365-4632.2004.02536.x. PMID 15985019.
51. Bazex, J, Bayle, P, San, B. (2007). "Hidradenitis suppurativa is acne inversa". International Journal of Dermatology. 46 (3): 330. doi:10.1111/j.1365-4632.2007.02872.x. PMID 17343599.{{cite journal}}: CS1 maint: multiple names: authors list (link)
52. Scheinfeld N (2006). "Hidradenitis should not be renamed acne inversa". Dermatol. Online J. 12 (7): 6. PMID 17459292.
53. Verneuil AS (1854). "Etudes sur les tumor de la peau". Arch Gen Med (in French). 94: 693.
54. Yu C.; Cook M. (1990). "Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands". Br J Dermatology. 122 (6): 763–69. doi:10.1111/j.1365-2133.1990.tb06264.x. PMID 2369556.
55. Boer J, Weltevreden EF (1996). "Hidradenitis suppurativa or Acne inversa. A clinicopathological study of early lesions". Br J Dermatol. 135 (5): 721–5. doi:10.1111/j.1365-2133.1996.tb03880.x. PMID 8977671.
56. Dessinioti, C; Katsambas, A; Antoniou, C (May–June 2014). "Hidradenitis suppurrativa (acne inversa) as a systemic disease". Clinics in Dermatology. 32 (3): 397–408. doi:10.1016/j.clindermatol.2013.11.006. PMID 24767187.

External links

• Medline: What is Hidradenitis Suppurativa?
• Hidradenitis Suppurativa (2004) Prof J. Revuz

• Use dmy dates from September 2010
• Acneiform eruptions
• Inflammations
• Rare diseases
• RTT